

PRESS RELEASE

IDOGEN AB



Corp. Reg. No. 556756-8521
Date: January 31, 2023

Idogen invited by GJCF to participate in their 3rd Summit for NMOSD Tolerization

Today, Idogen AB informed of their special invitation and participation as one of only 10 companies in The Guthy Jackson Charitable Foundation (GJCF) 3rd Summit for NMOSD Tolerization at the University of California, Los Angeles that took part 20-22 January. The companies represented a variety of tolerization technology platforms within autoimmune disorders.

In addition to GJCF leaders, 15 world-leading key opinion leaders and experts in the area of NMOSD and immune tolerance participated in the Summit. The Foundation is focused on novel solutions to the neuroinflammatory autoimmune disease, Neuromyelitis Optica Spectrum Disorder (NMOSD). As a field-leading event, the Summit will bring together pioneering technologies aimed at restoring immune tolerance to cure NMOSD.

“We were honored to be invited to this field-leading event of the GJCF. Idogen sees this invitation as a recognition of Idogen’s emerging cell therapy-based technology platform that has potential for use to tolerize NMOSD and perhaps other autoimmune diseases” says Christina Herder, acting CEO.

“Our goal is to restore immune tolerance in autoimmune disease by achieving antigen-specific tolerization. This strategy has great promise to arrest disease and spare patients the burden of life-long immunosuppressive therapy. NMOSD, and particularly the AQP4-positive disease form, is a highly attractive target indication because of its well-defined autoantigen, established biomarker and extensive depth of knowledge and collaboration led by the GJCF over the last decade. Therefore, it is a suitable disease model to be tested in our IDO AID program.” says Hanjing Xie, CMO.

IDO AID is Idogen’s program for autoimmune diseases, where there is a focus on orphan diseases.

The GJCF is a non-profit research and education foundation located in Los Angeles, California. Over its 15-year history, tremendous strides have been made through global collaborations to understand pathogenesis, more quickly and accurately diagnose, effectively treat and accelerate toward cures for those affected by NMOSD. More information about the GJCF can be found at: www.guthyjacksonfoundation.org.

For further information, please contact:

Christina Herder, acting CEO, Idogen AB
Tel: +46 70 374 71 56
E-mail: christina.herder@idogen.com

The information was submitted for publication through the agency of the contact persons set out above on January 31, 2023 at 13:17 CET.

Certified Adviser:

Vator Securities AB

Idogen (Nasdaq First North Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune

PRESS RELEASE

IDOGEN AB



system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company's most advanced program, IDO 8 – now in clinical phase – is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. For these hemophiliac patients, there is significant medical need for restoring the clinical effects of their treatment with factor VIII. This is a unique market positioning that over the long term could replace immune tolerance induction (ITI) treatments, with significant market potential. The planned IDO 8 clinical trial will validate the company's technology platform and facilitate a range of other applications in fields such as organ transplants (IDO T) and autoimmune diseases (IDO AID). More information about Idogen is available via www.idogen.com.